Literature DB >> 22086900

Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell response.

Christian L Seifert1, Christiane Wegner, Till Sprenger, Martin S Weber, Wolfgang Brück, Bernhard Hemmer, Johann Sellner.   

Abstract

We report a case of multiple sclerosis-associated fulminant tumefactive demyelinating lesion (TDL) with the special feature of delayed humoral immune response. Plasma exchange (PE) yielded significant benefit in two consecutive steroid-unresponsive relapses, while signs of an intrathecal B-cell response were only present 2 years later at the second relapse. Remission was achieved and sustained thereafter with natalizumab. Our case indicates that PE might be a therapeutic option even when the B-cell response is not fully developed. This delay in the development of a humoral immune response may reflect the step-wise B-cell colonization of the CNS and represent an attractive therapeutic window of opportunity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22086900     DOI: 10.1177/1352458511429012

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  12 in total

1.  Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.

Authors:  Klaus Lehmann-Horn; Helena C Kronsbein; Martin S Weber
Journal:  Ther Adv Neurol Disord       Date:  2013-05       Impact factor: 6.570

2.  Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis.

Authors:  Kristin M Ikeda; Donald H Lee; J Alexander Fraser; Seyed Mirsattari; Sarah A Morrow
Journal:  Int J MS Care       Date:  2015 Sep-Oct

3.  Contralateral recurrence of tumefactive demyelination.

Authors:  Mohammed Nazir Khan; Mihail Guranda; Marco Essig
Journal:  Neuroradiol J       Date:  2015-10-01

4.  Variant of multiple sclerosis with dementia and tumefactive demyelinating brain lesions.

Authors:  Sherifa A Hamed
Journal:  World J Clin Cases       Date:  2015-06-16       Impact factor: 1.337

Review 5.  The Role of Peripheral CNS-Directed Antibodies in Promoting Inflammatory CNS Demyelination.

Authors:  Silke Kinzel; Martin S Weber
Journal:  Brain Sci       Date:  2017-06-22

6.  Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis.

Authors:  Masataka Nakamura; Kumi Itani; Kousuke Miyake; Takenobu Kunieda; Satoshi Kaneko; Hirofumi Kusaka
Journal:  Intern Med       Date:  2017-01-15       Impact factor: 1.271

Review 7.  Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function.

Authors:  Klaus Lehmann-Horn; Silke Kinzel; Martin S Weber
Journal:  Int J Mol Sci       Date:  2017-09-23       Impact factor: 5.923

8.  Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments.

Authors:  Staley A Brod; J William Lindsey; Flavia Nelson
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-06-18

9.  A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann's syndrome.

Authors:  Sharmilee Gnanapavan; Zane Jaunmuktane; Kelly Pegoretti Baruteau; Sakthivel Gnanasambandam; Klaus Schmierer
Journal:  BMC Neurol       Date:  2014-04-02       Impact factor: 2.474

10.  Tumefactive demyelination with a transient appearance of oligoclonal bands in MS under fingolimod.

Authors:  Kazumasa Okada; Tomoyo Hashimoto; Masako Kobata; Shingo Kakeda; Toshiyuki Takahashi; Junko Hirato
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.